Changes in angiogenesis markers during neoadjuvant treatment for locally advanced breast cancer
https://doi.org/10.17650/1994-4098-2010-0-1-24-28
Abstract
The impact of various neoadjuvant treatment regimens on the level of enzyme immunoassay-determined angiogenic markers of endothelial growth factor and its type 2 receptor in tumor cytosol and serum was assessed in 30 patients with locally advanced breast cancer (BC). The findings suggest the promises for studies of neoangiogenesis factors mainly in tumor tissue for their possible use as prognostic biological markers in patients with BC.
About the Authors
E. A. Kim
I.M. Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
I. V. Vysotskaya
I.M. Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
N. E. Kushlinsky
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
V. P. Letyagin
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
E. S. Gershtein
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Folkman J. Tumor angiogenesis: ther- apeutic implications. N Engl J Med 1971;285:1182—6.
2. Кушлинский Н.Е., Герштейн Е.С. Роль фактора роста эндотелия сосудов при раке молочной железы. Бюлл эксп биол мед 2002;133:604—12.
3. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669—76.
4. Жукова Л.Г., Жуков Н.В., Личиницер М.Р. Экспрессия рецепторов VEGF FLT-1 и FLK-1 на опухолевых клетках — новый фактор прогноза при местно-распространенном раке молочной железы. Бюлл эксп биол мед 2003;135:478—81.
5. McMahon G. VEGF receptor signal- ing in tumor angiogenesis. Oncologist 2000;5:3—10.
6. Shibuya M., Ito N., Claesson-Welsh L. Structure and function of vascular endothelial growth factor receptor-1 and -2. Curr Top Microbiol Immunol 1999;237:59—83.
7. Щербаков А.М., Герштейн Е.С., Кушлинский Н.Е. и др. Фактор роста эндотелия сосудов, его рецепторы и антиапоптотические белки BCL-2 и AKT при раке молочной железы. Маммология 2006;(3):63—8.
8. Dvorak H.F. Vascular permeability fac- tor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;(20):4368—80.
9. Speirs V., Atkin S.L. Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cul- tures of epithelial and stromal cells derived from breast tumours. Br J Cancer 1999;80(5—6):898—903.
10. Герштейн Е.С., Кушлинский Н.Е. Биологические маркеры рака молочной железы: методологические аспекты и клинические рекомендации. Маммология 2005;(1):65—70.
11. Sledge G.W. Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. Semin Oncol 2002;29(Suppl 11):104—10.
12. Harmey J.H., Bouchier-Hayes D. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. Bioessays 2002;24:280—3.
13. Hope S. Rugo Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist 2004;9(Suppl 1):43—9.
14. Miller K.D. Issues and challenges for antiangiogenic therapies. Breast Cancer Res 2002;75:45—50.
Review
For citations:
Kim E.A., Vysotskaya I.V., Kushlinsky N.E., Letyagin V.P., Gershtein E.S. Changes in angiogenesis markers during neoadjuvant treatment for locally advanced breast cancer. Tumors of female reproductive system. 2010;(1):24-28. (In Russ.) https://doi.org/10.17650/1994-4098-2010-0-1-24-28
Views:
570
Email this article 